Cidara Therapeutics, Inc. entered into an Asset Purchase Agreement with NAPP Pharmaceutical Group Limited to sell its rezafungin acetate assets, including intellectual property rights, regulatory approvals, and contracts, in exchange for NAPP assuming certain liabilities.